Evidence map›Paper›PMID 27278018›Full record

ArticleJournal of cell science2016

Sorting nexin 9 negatively regulates invadopodia formation and function in cancer cells.

Nawal Bendris, Carrie J S Stearns, Carlos R Reis, Jaime Rodriguez-Canales, Hui Liu, Agnieszka W Witkiewicz, Sandra L Schmid

Abstract read
In one paragraph

Article in Journal of cell science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. PI(3,4)PProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Nawal BendrisDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX75390, USA nawal.bendris@utsouthwestern.edu sandra.schmid@utsouthwestern.edu.ORCID 0000-0002-6253-9752
Carrie J S StearnsDepartment of Molecular Medicine, Veterinary Medical Center, Cornell University, Ithaca, NY14853, USA.
Carlos R ReisDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX75390, USA.ORCID 0000-0002-8193-6964
Jaime Rodriguez-CanalesDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA.ORCID 0000-0002-0885-2377
Hui LiuDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA Department of Pathology, Xuzhou Medical College, Province of Jiangsu, China.
Agnieszka W WitkiewiczSimmons Cancer Center, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX390, USA.ORCID 0000-0001-9467-4169
Sandra L SchmidDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX75390, USA nawal.bendris@utsouthwestern.edu sandra.schmid@utsouthwestern.edu.ORCID 0000-0002-1690-7024
The University of Texas Southwestern Medical Center · USThe University of Texas MD Anderson Cancer Center · USCornell University · USSimmons University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
EARLY STEPS IN RECEPTOR-MEDIATED ENDOCYTOSISR01GM042455 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI METTLEN, MARCEL BERNARD · 1989 to 2020
$8.2M
The Clathrin Coated Vesicle CycleR01MH061345 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI SCHMID, SANDRA L. · 2010 to 2019
$5.0M
THE CLATHRIN COATED VESICLE CYCLER37MH061345 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI SCHMID, SANDRA L. · 2000 to 2009
$4.7M
Impact of ErbB2 and RB Pathways on DCIS Progression and TreatmentR01CA163863 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WITKIEWICZ, AGNIESZKA · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA163863NIGMS NIH HHS R01 GM042455NIMH NIH HHS R01 MH061345NIMH NIH HHS R37 MH061345
6 · The paper itself

Abstract

The ability of cancer cells to degrade the extracellular matrix and invade interstitial tissues contributes to their metastatic potential. We recently showed that overexpression of sorting nexin 9 (SNX9) leads to increased cell invasion and metastasis in animal models, which correlates with increased SNX9 protein expression in metastases from human mammary cancers. Here, we report that SNX9 expression is reduced relative to neighboring normal tissues in primary breast tumors, and progressively reduced in more aggressive stages of non-small-cell lung cancers. We show that SNX9 is localized at invadopodia where it directly binds the invadopodia marker TKS5 and negatively regulates invadopodia formation and function. SNX9 depletion increases invadopodia number and the local recruitment of MT1-MMP by decreasing its internalization. Together, these effects result in increased localized matrix degradation. We further identify SNX9 as a Src kinase substrate and show that this phosphorylation is important for SNX9 activity in regulating cell invasion, but is dispensable for its function in regulating invadopodia. The diversified changes associated with SNX9 expression in cancer highlight its importance as a central regulator of cancer cell behavior.

Indexed as

Adaptor Proteins, Vesicular TransportBiomarkers, TumorBreast NeoplasmsCell Line, TumorEndocytosisFemaleHEK293 CellsHumansLung NeoplasmsMatrix Metalloproteinase 14PhosphorylationPodosomesProtein BindingProtein TransportSorting Nexinssrc-Family KinasesAdaptor Proteins, Vesicular TransportBiomarkers, TumorMatrix Metalloproteinase 14SH3PXD2A protein, humanSNX9 protein, humanSorting Nexinssrc-Family KinasesExtracellular matrixInvadopodiaMT1-MMPSNX9Src kinaseTKS5

Identifiers

PMID27278018
PMCPMC4958298
OpenAlexW2410009696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.